Rhupus Syndrome and Efficacy of Etanercept Treatment

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rhupus Syndrome, Etanercept rhupus syndrome

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

About this study

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1

Exclusion criteria

those who had participated in other studies

Treatment and study plan

etanercept

Drug

25-mg etanercept injection subcutaneously twice a week

Other names: TNFа blockade

Primary outcomes

Disease Activity Score in 28 Joints (DAS28)

Time frame: 24 week

Sponsors and collaborators

Lead sponsor

Yang Beibei

Other

Registry information

Official study title

the First People's Hospital of Chenzhou

Important dates

Study start: 2013
Primary completion: 2014
Study completion: 2015
First posted: May 9, 2016
Registry last updated: May 9, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.